Skip to content
AnalystLens

Charles River Laboratories International Annual Report, Year Ended Dec 25, 2004

Filing Date
Filed March 9, 2005
Period End
December 25, 2004
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 10-K filed March 9, 2005. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. reported fiscal 2004 net sales of $766.9 milliona, up 25.0% from $613.7 million in 2003, and operating income of $160.3 million, compared with $138.6 million in 2003.

Net income was $89.8 millionb, or $1.68 per diluted share, versus $80.2 million, or $1.64 per diluted share, in 2003. Results include only the nine weeks of 2004 during which Inveresk Research Group, which was acquired in October 2004, was owned by the company. The filing states that Inveresk contributed 9.9% of the net sales gain and that operating margin was reduced by 2.2% from Inveresk-related amortization, stock-based compensation, and a $3.0 million Proteomics write-off.

The company reorganized into three segments. Research Models and Services generated $476.7 millionc, or 62.2% of 2004 net sales, with operating income of 32.0% of segment sales. Preclinical Services generated $266.0 million, or 34.7% of net sales, and grew 43.3%.

Clinical Services, newly created through Inveresk, contributed $24.3 milliond, or 3.2% of net sales. Backlog for Preclinical and Clinical Services was approximately $425.0 million at December 25, 2004. The Inveresk acquisition substantially changed the balance sheet.

Goodwill rose to $1.42 billion from $105.3 million, and total assets reached $2.63 billion from $799.6 million. Total debt was $685.8 million at year-end, compared with $186.0 million a year earlier, after a $400 million term loan and a $150 million revolving facility were put in place in October 2004. The filing cites risks from this debt level, from goodwill impairment, and from exchange-rate exposure, particularly to the pound sterling and Canadian dollar.

Key Highlights

  1. Net sales rose 25.0% to $766.9 million in 2004, and diluted EPS was $1.68 versus $1.64 in 2003.
  2. Inveresk Research Group was acquired in October 2004 for a purchase price of $1,458,057 thousand, and the filing states Inveresk contributed 9.9% to the net sales gain.
  3. Preclinical Services net sales grew 43.3% to $266.0 million, and the segment's operating income rose to $33.6 million.
  4. Total debt was $685.8 million at December 25, 2004, including a $400 million term loan and $100 million drawn on the revolver, versus $185.9 million a year earlier.
  5. Goodwill increased to $1.42 billion, and the filing warns that any impairment could materially affect operating results.
  6. The filing reports backlog of approximately $425.0 million for Preclinical and Clinical Services at year-end 2004.
  7. The company reports that international revenues were 36.3% of 2004 net sales, up from 30.8% in 2003.

Frequently Asked Questions

  1. What drove the growth in 2004 net sales?

    The filing attributes the 25.0% increase to the Inveresk acquisition, which contributed 9.9% of the gain, and favorable foreign currency translation, which contributed about 2.9%. Research Models and Services sales grew 11.3%, supported by price increases of up to 5% and higher demand for specialty models.

  2. How much debt does the company carry after the Inveresk acquisition?

    Total debt was $685.8 million at December 25, 2004. The filing lists $185.0 million of senior convertible debentures, a $400.0 million term loan, and $100.0 million drawn on the revolving credit facility. Contractual debt payments of $80.5 million are due within one year.

  3. Does the company pay dividends?

    No. The filing states the company has not declared or paid cash dividends on its common stock in the past two years, except to former parent companies, and does not intend to pay cash dividends in the foreseeable future. Its credit agreements also restrict dividend payments.

  4. What are the main risks highlighted in the filing?

    The filing highlights risks from international operations, reductions in pharmaceutical R&D or government research funding, outsourcing trends, and the debt level. It also cites goodwill impairment risk from Inveresk, exchange-rate exposure, and the possible loss of certain UK and Canadian tax benefits.